Release Date: Monday, April 4, 2016     Expiration Date: Tuesday, April 4, 2017

Opioids are increasingly prescribed to treat chronic cancer and noncancer pain. Opioid-induced constipation (OIC) is one of the most common and troublesome adverse events associated with opioids, impacting the majority of patients being treated for chronic pain. In addition to the clinical consequences, OIC is also associated with diminished quality of life, compromised pain management, and increased use of healthcare resources. For many, laxatives remain the treatment of choice in preventing and managing OIC, but these agents are associated with significant limitations and risks. More recent advancements have led to the development of a more targeted approach that specifically counteracts the effects of opioids in the gastrointestinal tract. As the role of pharmacists in managing patients with chronic pain grows within the multidisciplinary team, it is imperative that pharmacists improve their competence in the prevention and treatment of OIC. This can include utilizing effective prevention strategies, recognizing the early signs of OIC, and selecting the optimal approach to treat OIC based on patient-specific factors. This program provides an overview of the burden and pathophysiology of OIC and offers practical solutions in the prevention and treatment of OIC through case-based discussions.


This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, community pharmacies, and academia. This program targets pharmacists who are involved in the management of patients with or at-risk for OIC.



Upon completing this activity, participants will be able to:

  • Discuss the impact of opioid medications on bowel function and recognize patients at risk for opioid-induced constipation (OIC)
  • Utilize proactive approaches to prevent OIC among patients initiating or continuing to use opioid medications
  • Evaluate the use of newer, non-laxative, pharmacotherapeutic agents in the management of OIC based on patient factors

This webcast on demand is based on the CPE Satellite Symposium conducted at APhA 2016

The webcast on demand consists of following sections:

• Opioid-Induced Constipation: Recognizing the Burden
• Pathophysiology and Prevention of OIC
• Knowing the Treatment Options

Note: If you have received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version.


Gregory L. Holmquist, PharmD, CPE

Pain and Palliative Care Specialist
Certified Pain Educator
Palliative Care Strategies

Seattle, WA



Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credits for participating in this activity.
 ACPE UAN: UAN: 0473-9999-16-005-H01-P
Activity type: Knowledge-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CE information including target audience, learning objectives, and disclosures.
  2. Review entire activity.
  3. Complete the Post Test, Evaluation, and Credit Application Form.
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit


Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Gregory L. Holmquist, PharmD has relevant financial relationships with the following commercial interests: Consultant: Depomed, Salix, AstraZeneca
Dr. Holmquist does not discuss off-label uses of any products.

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2016 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Salix, a Division of Valeant Pharmaceuticals North America


By clicking below, I acknowledge that I have read the entire CE information.